Wei Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Zhou has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Zhan-Ting Li
State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200032, China
24 shared publications - David Wei Zhang
State Key Lab of ASIC & Systems, Fudan University, Shanghai 201203, China
22 shared publications Hui Wang
Department of Chemistry, Fudan University, 2205 Songhu Road, Shanghai, 200438, China
13 shared publications- Shang-Bo Yu
State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 345 Lingling Lu, Shanghai 200032, China
11 shared publications - Yue-Yang Liu
Department of Chemistry, Fudan University, 2205 Songhu Road, Shanghai 200438, China
7 shared publications - Da Ma
School of Pharmaceutical and Chemical Engineering & Institute for Advanced Studies, Taizhou University, 1139 Shifu Avenue, Taizhou 318000, Zhejiang, China
6 shared publications
Latest Publications
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13966-13979
Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs
Halogenation has been used as a useful strategy to optimize an imidazolium-based macrocyclic ultralong-acting neuromuscular blocking agent for improved bioactivity and biocompatibility. A structure–activity relationship study for 18 compounds reveals that monofluorinated macrocycle IMC-X5 displays blockade profiles generally superior to those of lead compound IMC-0. In vivo tests with a rat model show that, compared with those of IMC-0, the onset, profound blockade, and moderate blockade-to-spontaneous respiration times of IMC-X5 at the same dose of 0.2 mg/kg shortens by 47%, extends by 34%, and shortens by 89%, respectively, while the onset activity surpasses that of cisatracurium, one of the main neuromuscular blocking agents, of a clinically associated dose. Moreover, the profound blockade of IMC-X5 can be rapidly reversed by a biocompatible acyclic cucurbit[n]uril (ACB) antagonist at any stage of blockade. IMC-X5 also exhibits a biosafety superior to that of IMC-0. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.
- 29 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13966-13979
Fluorinated Ultralong-Acting Neuromuscular Blocking Agent with Improved Activity Profile and Biosafety for the Development of Blockade and Reversal Partner Drugs
Halogenation has been used as a useful strategy to optimize an imidazolium-based macrocyclic ultralong-acting neuromuscular blocking agent for improved bioactivity and biocompatibility. A structure–activity relationship study for 18 compounds reveals that monofluorinated macrocycle IMC-X5 displays blockade profiles generally superior to those of lead compound IMC-0. In vivo tests with a rat model show that, compared with those of IMC-0, the onset, profound blockade, and moderate blockade-to-spontaneous respiration times of IMC-X5 at the same dose of 0.2 mg/kg shortens by 47%, extends by 34%, and shortens by 89%, respectively, while the onset activity surpasses that of cisatracurium, one of the main neuromuscular blocking agents, of a clinically associated dose. Moreover, the profound blockade of IMC-X5 can be rapidly reversed by a biocompatible acyclic cucurbit[n]uril (ACB) antagonist at any stage of blockade. IMC-X5 also exhibits a biosafety superior to that of IMC-0. The two agents thus form a promising partnership featuring ultralong-acting blockade and on-demand reversal.
- 5 May 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (20) , 6355-6363
Perfluoroalkylated amphiphilic porphyrin nanomicelles for improved photodynamic therapy: anti-tumour efficacy through stability enhancement and O 2 enrichment
Perfluoroalkyl chains form a fluorocarbon microphase that stabilizes nanomicelles assembled with a trianionic porphyrin amphiphile and enriches O 2 in the nanomicelles, leading to the enhancement of photodynamic activity.
- 5 May 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (20) , 6355-6363
Perfluoroalkylated amphiphilic porphyrin nanomicelles for improved photodynamic therapy: anti-tumour efficacy through stability enhancement and O 2 enrichment
Perfluoroalkyl chains form a fluorocarbon microphase that stabilizes nanomicelles assembled with a trianionic porphyrin amphiphile and enriches O 2 in the nanomicelles, leading to the enhancement of photodynamic activity.
- 3 February 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (3) , 1331-1340
Deuteration for enhancing the antagonistic activity of an acyclic cucurbit[n]uril for neuromuscular blocking agents through host-guest complexation
- 3 February 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (3) , 1331-1340
Deuteration for enhancing the antagonistic activity of an acyclic cucurbit[n]uril for neuromuscular blocking agents through host-guest complexation
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1752-1765
Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants
The development of a biocompatible antidote that can efficiently neutralize the anticoagulation activity of both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) represents an unmet medical need. Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction.
- 7 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (2) , 1752-1765
Discovery of a Piperazine-Based Quaternary Ammonium Macrocycle as a Universal Reversal Agent for Heparin Anticoagulants
The development of a biocompatible antidote that can efficiently neutralize the anticoagulation activity of both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) represents an unmet medical need. Here, we report that a piperazine-derived tetracationic macrocycle can efficiently neutralize both UFH and LMWHs, including dalteparin, enoxaparin, and nadroparin. In vitro and in vivo assays reveal that the compound outperforms protamine, exhibiting significantly improved neutralization activity, a broad therapeutic window for all heparins, and high biocompatibility, which is confirmed by its very low coagulation and hemolysis effect, as well as a high therapeutic index (20.5), defined as the ratio of the maximum tolerated dose to the effective therapeutic dose. Molecular dynamics simulations indicate that binding may occur through interlocked threading and direct contact patterns, which are stabilized by intermolecular hydrogen bonding and ion-pair electrostatic attraction.
- Open Access
- 1 January 2026
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 46 (9) , 3722
Acyclic Cucurbit[ n ]uril as Supramolecular Antagonist for Rapidly Reversing the Neuromuscular Blockade of Succinylcholine through Host-Guest Complexation
- 1 January 2026
- Published by Shanghai Institute of Organic Chemistry in Chinese Journal of Organic Chemistry
- Vol. 46 (9) , 3722
Open AccessAcyclic Cucurbit[ n ]uril as Supramolecular Antagonist for Rapidly Reversing the Neuromuscular Blockade of Succinylcholine through Host-Guest Complexation
- 8 December 2025
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 7 (24) , 17125-17133
Cucurbit[8]uril-Derived Porous Organic Polymer Adsorbents for Highly Efficient, Recyclable Removal of Endocrine Disrupting Chemicals
- 8 December 2025
- Published by American Chemical Society (ACS) in ACS Applied Polymer Materials
- Vol. 7 (24) , 17125-17133
Cucurbit[8]uril-Derived Porous Organic Polymer Adsorbents for Highly Efficient, Recyclable Removal of Endocrine Disrupting Chemicals
- Open Access
Bioactive Secondary Metabolites of Two Chinese Edible Boletes, Phlebopus portentosus and Butyriboletus roseoflavus
This study investigated the phytochemical profiles and bioactivities of two edible boletes from Southwestern China, Phlebopus portentosus and Butyriboletus roseoflavus. A total of 33 secondary metabolites, comprising 15 alkaloids, 4 pulvinic acid derivative pigments, and 14 ergosterols, were isolated and identified. To our best knowledge, boletesine A (1), boletesine B (2), and cis-xerocomic acid (16) were previously undescribed compounds. The new structures were established by extensive spectroscopic methods and chemical calculations. Compound 1 features a hitherto unknown hybrid skeleton formed between a 2-formylpyrrole-alkaloid and a dopacetic acid (DOPAC) via a Michael addition reaction. Bioactivity assays revealed the neuroprotective effects of compounds 18 and 19 against Aβ25–35- or H2O2-induced toxicity. In a cytotoxic assay against a small panel of cancer cell lines, compound 9 exhibited significant activity against HeLa cells (IC50 = 10.76 µM), while 33 demonstrated broad-spectrum cytotoxicity against Hela229, SGC7901, PC-3, and BEL7402 cells (IC50s in the range of 20~30 µM). Of particular note is the anti-influenza virus activities against A/H3N2 and B/Victoria strains of compounds 22 and 26 (EC50 values ranging from 3.6 to 9.6 µM). Along with these, compound 29 showed a moderate antiviral effect against coxsackievirus B3. These findings underscore the therapeutic potential of the two edible boletes in addressing neurodegenerative diseases, cancer, and viral infections, paving the way for their prospective applications in the development of functional foods and pharmaceuticals.
Open AccessBioactive Secondary Metabolites of Two Chinese Edible Boletes, Phlebopus portentosus and Butyriboletus roseoflavus
This study investigated the phytochemical profiles and bioactivities of two edible boletes from Southwestern China, Phlebopus portentosus and Butyriboletus roseoflavus. A total of 33 secondary metabolites, comprising 15 alkaloids, 4 pulvinic acid derivative pigments, and 14 ergosterols, were isolated and identified. To our best knowledge, boletesine A (1), boletesine B (2), and cis-xerocomic acid (16) were previously undescribed compounds. The new structures were established by extensive spectroscopic methods and chemical calculations. Compound 1 features a hitherto unknown hybrid skeleton formed between a 2-formylpyrrole-alkaloid and a dopacetic acid (DOPAC) via a Michael addition reaction. Bioactivity assays revealed the neuroprotective effects of compounds 18 and 19 against Aβ25–35- or H2O2-induced toxicity. In a cytotoxic assay against a small panel of cancer cell lines, compound 9 exhibited significant activity against HeLa cells (IC50 = 10.76 µM), while 33 demonstrated broad-spectrum cytotoxicity against Hela229, SGC7901, PC-3, and BEL7402 cells (IC50s in the range of 20~30 µM). Of particular note is the anti-influenza virus activities against A/H3N2 and B/Victoria strains of compounds 22 and 26 (EC50 values ranging from 3.6 to 9.6 µM). Along with these, compound 29 showed a moderate antiviral effect against coxsackievirus B3. These findings underscore the therapeutic potential of the two edible boletes in addressing neurodegenerative diseases, cancer, and viral infections, paving the way for their prospective applications in the development of functional foods and pharmaceuticals.
- 26 February 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (4) , 2259-2265
Amphiphilic Acyclic Cucurbit[n]uril: Synthesis, Self-Assembly, and Chemotherapeutic Delivery to Overcome Multidrug Resistance
A new amphiphilic acyclic cucurbit[n]uril (CB[n]) is designed and synthesized. This amphiphilic acyclic CB[n] could encapsulate pharmaceutical drugs via a host-guest interaction. Self-assembly of this acyclic CB[n] forms spherical nanoparticles with diameters of 91 nm in water. The self-assembled nanoparticles are capable of delivering doxorubicin with high efficiency. Cell experiments show that the doxorubicin-loaded nanoparticles can improve cellular uptake and cytotoxicity by using the MCF-7/ADR cell line. The A549 tumor-bearing mouse model shows that self-assembled nanoparticles help overcome multidrug resistance in vivo. Cell study and histological assays confirm the biocompatibility of self-assembled nanoparticles.
- 26 February 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (4) , 2259-2265
Amphiphilic Acyclic Cucurbit[n]uril: Synthesis, Self-Assembly, and Chemotherapeutic Delivery to Overcome Multidrug Resistance
A new amphiphilic acyclic cucurbit[n]uril (CB[n]) is designed and synthesized. This amphiphilic acyclic CB[n] could encapsulate pharmaceutical drugs via a host-guest interaction. Self-assembly of this acyclic CB[n] forms spherical nanoparticles with diameters of 91 nm in water. The self-assembled nanoparticles are capable of delivering doxorubicin with high efficiency. Cell experiments show that the doxorubicin-loaded nanoparticles can improve cellular uptake and cytotoxicity by using the MCF-7/ADR cell line. The A549 tumor-bearing mouse model shows that self-assembled nanoparticles help overcome multidrug resistance in vivo. Cell study and histological assays confirm the biocompatibility of self-assembled nanoparticles.
- 25 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 140, 156577
Baicalein inhibits hepatitis B virus through the coiled coil domain containing protein 88A (CCDC88A)-dependent autophagy pathway
- 25 February 2025
- Published by Elsevier in Phytomedicine
- Vol. 140, 156577
Baicalein inhibits hepatitis B virus through the coiled coil domain containing protein 88A (CCDC88A)-dependent autophagy pathway
- 24 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7031-7043
Discovery of an Ultralong-acting Nondepolarizing Neuromuscular Blocker That Displays Short Onset Time and On-Demand Rapid Reversal by a Biocompatible Antagonist
The combination of ultralong-acting neuromuscular block and subsequent on-demand rapid reversal may provide prolonged surgeries with improved conditions by omitting continuous or repetitive blocker administration, enabling a more stable and predictable hemodynamic profile and eliminating residual block. For this target, we prepared 19 imidazolium-incorporated tetracationic macrocycles. In vivo studies with rats revealed that one macrocycle (IMC-14) displays extremely high blocking activity. At the dose of 12.5-fold ED90, IMC-14 exhibits an onset time shorter than that of cisatracurium of 2-fold dose and a duration time corresponding to more than 13 h for human adults. Moreover, within the dose range of 12.5-187.5-fold ED90, the profound block induced by IMC-14 can be rapidly reversed at any stage by a highly biocompatible acyclic cucurbit[n]uril antagonist, with a reversal time significantly shorter than that achieved by sugammadex for reversing the block of rocuronium, a clinically widely used intermediate-acting neuromuscular blocking agent.
- 24 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (7) , 7031-7043
Discovery of an Ultralong-acting Nondepolarizing Neuromuscular Blocker That Displays Short Onset Time and On-Demand Rapid Reversal by a Biocompatible Antagonist
The combination of ultralong-acting neuromuscular block and subsequent on-demand rapid reversal may provide prolonged surgeries with improved conditions by omitting continuous or repetitive blocker administration, enabling a more stable and predictable hemodynamic profile and eliminating residual block. For this target, we prepared 19 imidazolium-incorporated tetracationic macrocycles. In vivo studies with rats revealed that one macrocycle (IMC-14) displays extremely high blocking activity. At the dose of 12.5-fold ED90, IMC-14 exhibits an onset time shorter than that of cisatracurium of 2-fold dose and a duration time corresponding to more than 13 h for human adults. Moreover, within the dose range of 12.5-187.5-fold ED90, the profound block induced by IMC-14 can be rapidly reversed at any stage by a highly biocompatible acyclic cucurbit[n]uril antagonist, with a reversal time significantly shorter than that achieved by sugammadex for reversing the block of rocuronium, a clinically widely used intermediate-acting neuromuscular blocking agent.